0001437749-22-020338.txt : 20220812 0001437749-22-020338.hdr.sgml : 20220812 20220812160219 ACCESSION NUMBER: 0001437749-22-020338 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220810 FILED AS OF DATE: 20220812 DATE AS OF CHANGE: 20220812 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: HIGGINS JOHN L CENTRAL INDEX KEY: 0001208906 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-17272 FILM NUMBER: 221159904 MAIL ADDRESS: STREET 1: 11119 NORTH TORREY PINES ROAD, SUITE 200 CITY: LA JOLLA STATE: CA ZIP: 92037 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: BIO-TECHNE Corp CENTRAL INDEX KEY: 0000842023 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 411427402 STATE OF INCORPORATION: MN FISCAL YEAR END: 0630 BUSINESS ADDRESS: STREET 1: 614 MCKINLEY PL N E CITY: MINNEAPOLIS STATE: MN ZIP: 55413 BUSINESS PHONE: 6123798854 MAIL ADDRESS: STREET 1: 614 MCKINLEY PLACE NE CITY: MINNEAPOLIS STATE: MN ZIP: 55413 FORMER COMPANY: FORMER CONFORMED NAME: TECHNE CORP /MN/ DATE OF NAME CHANGE: 19920703 4 1 rdgdoc.xml FORM 4 X0306 4 2022-08-10 0000842023 BIO-TECHNE Corp TECH 0001208906 HIGGINS JOHN L 11085 NORTH TORREY PINES ROAD SUITE 300 LA JOLLA CA 92037 1 Common Stock 2022-08-10 4 M 0 3400 66.90 A 8006 D Common Stock 2022-08-10 4 S 0 900 373.9918 D 7106 D Common Stock 2022-08-10 4 S 0 100 374.8950 D 7006 D Common Stock 2022-08-10 4 S 0 992 380.153 D 6014 D Common Stock 2022-08-11 4 S 0 504 385.4694 D 5510 D Common Stock 2022-08-11 4 S 0 8 380.71 D 5502 D Stock Option (right to buy) 66.90 2022-08-10 4 M 0 3400 0 D 2012-10-25 2022-10-24 Common Stock 3400 0 D Stock Option (right to buy) 87.3900 2013-10-31 2023-10-30 Common Stock 4000 4000 D Stock Option (right to buy) 91.7800 2014-10-30 2024-10-30 Common Stock 4000 4000 D Stock Option (right to buy) 87.3400 2016-10-29 2025-10-28 Common Stock 4260 4260 D Stock Option (right to buy) 101.1900 2017-10-26 2026-10-26 Common Stock 3985 3985 D Stock Option (right to buy) 125.0500 2018-10-25 2027-10-27 Common Stock 3125 3125 D Stock Option (right to buy) 179.8400 2019-10-24 2028-10-25 Common Stock 1898 1898 D Stock Option (right to buy) 201.6400 2020-10-24 2029-10-24 Common Stock 2011 2011 D Stock Option (right to buy) 255.6900 2021-10-28 2030-10-29 Common Stock 1507 1507 D Stock Option (right to buy) 515.2400 2031-10-28 Common Stock 633 633 D The option vests on the earlier of the one year anniversary of the grant date (10/28/21) or the date of Bio-Techne's 2022 annual meeting of shareholders. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from 373.8600 to 374.3300, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from 374.8950 to 374.9000, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from 380.0000 to 380.4400, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from 385.2900 to 385.8900, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. /s/ Brenda S. Furlow, Attorney-in-Fact 2022-08-12